MaxCyte: Gold standard technology draws CRISPR pioneer Caribou
MaxCyte’s new clinical and commercial licence agreement with Caribou Biosciences, which allows the use of its proprietary Flow Electroporation technology for Caribou’s CRISPR gene-edited allogeneic T-cell therapy programmes is the latest in a series of late-stage clinical and commercial collaborations in cell and gene therapy. The agreement demonstrates MXCT’s expertise and the value of its Flow Electroporation technology, which is rapidly being adopted as the gold standard in non-viral cell and gene engineering. It is clearly profile-raising, enhances the likelihood of milestone release and cements its position yet further in the field.
Quick facts: MaxCyte Inc
Price: 370 GBX
Market Cap: £285.49 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of MaxCyte Inc named herein, including the promotion by the Company of MaxCyte Inc in any Content on the Site, the Company receives from said...FOR OUR FULL DISCLAIMER CLICK HERE
LEGAL NOTICE – IMPORTANT – PLEASE READ:
Proactive Research is a trading name of Proactive Investors Limited which is regulated and authorised by the Financial Conduct Authority (FCA) under firm registration...FOR OUR FULL DISCLAIMER CLICK HERE